ZANAMIVIR

Zanamivir is a neuraminidase inhibitor used for influenza A and B, blocking viral release. Delivered by inhalation. Side effects include bronchospasm, cough, headache, and rare allergic reactions. Only GMP materials will be supplied, logistics all according to GDP.

SKU: 61053bb63f8f Category: Tag:

Product Description


Mechanism of Action

ZANAMIVIR demonstrates a multiaxis biochemical interference profile spanning catalyticdomain perturbation, mitochondrialnetwork recalibration, ionflux redistribution, membranepotential modulation, cytoskeletal remodelling, redoxequilibrium restructuring and transcriptionfactor pathway reprogramming. Its molecular architecture supports docking to catalytic residues, allosteric control nodes, transmembrane helices, nucleotidebinding sites, redoxbuffer matrices and polymeric scaffold proteins. This enables systemwide modulation across metabolic, structural, genomic and electrophysiological regulatory layers.

Mechanistic effects include redistribution of phosphorylation flux across ERK/MAPK/JNK/p38 signalling axes, modulation of PI3KAKT survivalpathway geometry, reconfiguration of Gprotein coupling logic, reshaping of Ca²⁺ microdomain behaviour, alteration of IP/DAG cascade topology and amplitude recalibration within the cAMPPKA axis. Mitochondrial influences include ETCcomplex rebalancing, ATP/ADP flux modelling shifts, ROSthreshold displacement, mitochondrialmembrane potential polarity adjustments and crossorganelle stresssignal propagation between ER and mitochondrial systems.

Advanced

  • Kinomelevel catalyticcascade interference mapping
  • Highprecision ligand docking & conformationaltransition simulations
  • UPR/ERstress, mitophagy & autophagicflux network modelling
  • Multiomics integration (RNAseq, proteomics, metabolomics, phosphoproteomics)
  • Cytoskeletal mechanics, forcedistribution profiling & polymer turnover
  • Cellfate modelling across apoptosis, necroptosis, ferroptosis & parthanatos
  • SAR/QSAR optimisation with machinelearningbased compound performance modelling

Toxicodynamics & Hazard Spectrum

  • Rapid ROS accumulation & antioxidantbuffer collapse
  • Mitochondrial fragmentation or ETC suppression
  • Severe Na⁺/K⁺/Ca²⁺ ionflux destabilisation
  • Cytoskeletal depolymerisation & membrane-integrity failure
  • Hyperactivation of NF-κB, STAT & IRF inflammatory regulators
  • Induction of multiaxis programmed-cell-death pathways
  • Epigenetic drift including methylation/acetylation instability

For expert laboratory research only not intended for biological use.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C12H20N4O7

Molecular Weight

332.31 g/mol

CAS Number

139110-80-8

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

In water, 18,000 mg/L at 25 °C

Purity

Purity information is available upon request (COA).

Synonym

zanamivir; 139110-80-8; Relenza; GANA; 4-Guanidino-Neu5Ac2en

IUPAC/Chemical Name

(2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid

InChl Key

ARAIBEBZBOPLMB-UFGQHTETSA-N

InChl Code

InChI=1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/60855;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download